Categories: Wire Stories

JSR Life Sciences� Amsphere A3 Integrated into the Commercial Manufacturing of FDA-Approved Antibody Therapy

Launch marks product�s first use in a commercial therapeutic

SUNNYVALE, Calif.–(BUSINESS WIRE)–JSR Life Sciences, LLC today announced that its lead product, Amsphere™ A3, has been incorporated for the first time into the commercial manufacturing of an FDA-approved treatment.

Amsphere™ A3 is a next generation Protein-A chromatography resin that enables advanced protein separation in downstream processing of therapeutic antibodies. Since its launch in January 2016, the product has seen rapid adoption as an alternative option for downstream purification in biologics processing.

“The support provided by our global applications teams really helped make this happen,” said Hideaki Nomura, general manager of JSR Life Sciences’ Bioprocess Division. “Despite international supply chain disruptions affecting most global companies, we are in a position not only to maintain our commitments, but to expand our bioprocess purification materials to support more biologics companies in their pursuit of promising treatments for patients.”

The company is currently expanding on all fronts to facilitate increased manufacturing of biologics. Along with its first commercial launch, Amsphere™ A3 is currently being used in more than 95 clinical programs worldwide.

About JSR Life Sciences, LLC

A business unit of JSR Corporation, JSR Life Sciences, LLC is changing human health as a strategic partner and pathfinder for the life sciences industry. Rooted in a history of materials innovation, JSR Life Sciences provides specialized products, materials, and services to biopharmaceutical companies and academic researchers. Together with its world-class affiliates, JSR Life Sciences offers best-in-class integrated services that de-risk molecule selection, accelerate biologic development timelines, increase clinical success rates, and develop novel in vitro diagnostics. JSR Life Sciences’ global network of affiliates includes Crown Bioscience Inc., KBI Biopharma, Inc., Selexis SA, and MEDICAL & BIOLOGICAL LABORATORIES CO., LTD. The company operates R&D and applications labs, manufacturing facilities, and sales offices worldwide. For more information, visit JSRLifeSciences.com.

Contacts

Missy Bindseil

JSR Life Sciences Company Inquiries

Director, Marketing & Communications

mbindseil@jsr-nahq.com

Mike Beyer

JSR Life Sciences Media Inquiries

Sam Brown Inc.

mikebeyer@sambrown.com
+1 312-961-2502

Alex

Recent Posts

JINGDONG Logistics Expands Middle East Presence with 5 Warehouses, Offering Premium Services Across MENA Markets

RIYADH, SAUDI ARABIA - Media OutReach Newswire - 1 April 2025 - Recently, at JINGDONG…

39 minutes ago

VT Markets Releases Q2 Report On U.S. Dollar Dominance Shift as Central Bank Diverge

HONG KONG SAR - Media OutReach Newswire – 1 April 2025 - Leading global financial…

1 hour ago

Prudential partners Thomson Medical Centre to offer more healthcare options and convenience for customers

SINGAPORE - Media OutReach Newswire - 1 April 2025 - Prudential Singapore ("Prudential") and Thomson…

1 hour ago

SonicWall’s Zero Trust Network Access (ZTNA) Solutions Driving Success Tackling 2025’s Biggest Cybersecurity Challenges

One Year After Acquiring Banyan Security, SonicWall’s Cloud Secure Edge/ZTNA Remote Access Solutions See Remarkable…

3 hours ago

MSIG launches TravelEasy Flex, an affordable travel insurance that can be tailored to policyholder’s needs

Study reveals travellers’ top priorities when buying travel insurance SINGAPORE - Media OutReach Newswire -…

4 hours ago

BFSI Security Summit 2025 to Address Rising Cybersecurity Threats in Africa’s Financial Sector

JOHANNESBURG, SOUTH AFRICA - Media OutReach Newswire - 1 April 2025 - The BFSI Security…

5 hours ago